Smith+Nephew to attend AAOS 2024 Annual
Meeting
12
February 2024
Smith+Nephew (LSE:SN, NYSE:SNN), the
global medical technology company, announces that it will be
attending the American Academy of Orthopaedic Surgeons (AAOS) 2024
Annual Meeting running from 12 to 16 February 2024 in San
Francisco.
A number of commercial press releases
are planned to coincide with AAOS, including:
·
In Orthopaedics Reconstruction, confirmation of
our leading robotic-assisted solutions for personalised orthopaedic
surgery on show.
·
In Trauma and Extremities, notification of the
commercial launch of the AETOS◊ Shoulder
System.
·
In Sports Medicine, the premiere of our expanded
biological healing portfolio, including the newly acquired
CARTIHEAL AGILI-C◊ Cartilage Repair Implant alongside
new applications for the REGENETEN◊ Bioinductive
Implant.
In-line with prior years,
Smith+Nephew will be hosting investors and financial analysts
attending the show, including booth tours showcasing our
products.
There will be no new information
provided on current trading performance or financial targets at
AAOS. Smith+Nephew will publish its Fourth Quarter and Full Year
2023 results on 27 February 2024.
Enquiries
Investors/ Analysts
Andrew Swift
+44 (0) 1923 477433
Katharine
Rycroft
+44 (0) 7811 270734
Smith+Nephew
Media
Charles Reynolds
+44 (0) 1923 477314
Smith+Nephew
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology business that exists to restore people's bodies and
their self-belief by using technology to take the limits off
living. We call this purpose 'Life Unlimited'. Our 19,000 employees
deliver this mission every day, making a difference to patients'
lives through the excellence of our product portfolio, and the
invention and application of new technologies across our three
global business units of Orthopaedics, Advanced Wound Management
and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we
now operate in more than 100 countries, and generated annual sales
of $5.2 billion in 2022. Smith+Nephew is a constituent of
the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and
'Smith+Nephew' are used to refer to Smith & Nephew plc and its
consolidated subsidiaries, unless the context requires
otherwise.
For more information about
Smith+Nephew, please visit www.smith-nephew.com and
follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking
Statements
This document may contain
forward-looking statements that may or may not prove accurate. For
example, statements regarding expected revenue growth and trading
profit margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: economic
and financial conditions in the markets we serve, especially those
affecting healthcare providers, payers and customers; price levels
for established and innovative medical devices; developments in
medical technology; regulatory approvals, reimbursement decisions
or other government actions; product defects or recalls or other
problems with quality management systems or failure to comply with
related regulations; litigation relating to patent or other claims;
legal and financial compliance risks and related investigative,
remedial or enforcement actions; disruption to our supply chain or
operations or those of our suppliers; competition for qualified
personnel; strategic actions, including acquisitions and disposals,
our success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; relationships with healthcare
professionals; reliance on information technology and
cybersecurity; disruptions due to natural disasters, weather and
climate change related events; changes in customer and other
stakeholder sustainability expectations; changes in taxation
regulations; effects of foreign exchange volatility; and numerous
other matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith+Nephew has filed with
the U.S. Securities and Exchange Commission under
the U.S. Securities Exchange Act of 1934, as amended,
including Smith+Nephew's most recent annual report on Form 20-F,
which is available on the SEC's website at www. sec.gov, for a
discussion of certain of these factors. Any forward-looking
statement is based on information available to Smith+Nephew as of
the date of the statement. All written or oral forward-looking
statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update
or revise any forward-looking statement to reflect any change in
circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew.
Certain marks registered in US Patent and Trademark
Office.